Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
$6.37
-2.6%
$5.93
$3.91
$21.26
$437.80M1.39885,620 shs805,154 shs
Fluidigm Co. stock logo
FLDM
Fluidigm
$3.66
$2.67
$7.51
$283.76M1.14968,838 shs60,126 shs
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
$0.38
-3.3%
$0.62
$0.36
$4.08
$16.66M1.47200,970 shs355,881 shs
Transcat, Inc. stock logo
TRNS
Transcat
$85.13
+0.1%
$77.14
$67.56
$147.12
$792.48M0.6773,909 shs29,523 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
0.00%+12.15%+9.26%-20.57%-61.97%
Fluidigm Co. stock logo
FLDM
Fluidigm
0.00%0.00%0.00%0.00%0.00%
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
0.00%-2.86%-38.21%-79.06%-89.59%
Transcat, Inc. stock logo
TRNS
Transcat
0.00%+0.64%+16.01%-14.28%-22.49%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
1.6988 of 5 stars
3.50.00.00.03.61.70.0
Fluidigm Co. stock logo
FLDM
Fluidigm
N/AN/AN/AN/AN/AN/AN/AN/A
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
3.7367 of 5 stars
3.33.00.04.50.91.70.6
Transcat, Inc. stock logo
TRNS
Transcat
2.7285 of 5 stars
3.21.00.00.03.23.31.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
3.00
Buy$26.63317.97% Upside
Fluidigm Co. stock logo
FLDM
Fluidigm
0.00
N/AN/AN/A
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
2.50
Moderate Buy$4.501,093.95% Upside
Transcat, Inc. stock logo
TRNS
Transcat
2.40
Hold$111.5030.98% Upside

Current Analyst Ratings Breakdown

Latest EYPT, FLDM, HBIO, and TRNS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/9/2025
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Sector Weight
3/24/2025
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSpeculative Buy ➝ Speculative Buy$5.50 ➝ $4.50
3/6/2025
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$33.00 ➝ $33.00
3/6/2025
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
2/6/2025
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$33.00 ➝ $33.00
1/29/2025
Transcat, Inc. stock logo
TRNS
Transcat
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$126.00 ➝ $106.00
1/29/2025
Transcat, Inc. stock logo
TRNS
Transcat
Northland Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform ➝ Market Perform$110.00 ➝ $85.00
1/29/2025
Transcat, Inc. stock logo
TRNS
Transcat
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
(Data available from 4/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
$43.27M10.12N/AN/A$5.66 per share1.13
Fluidigm Co. stock logo
FLDM
Fluidigm
$130.58M0.00N/AN/A$1.24 per share0.00
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
$94.14M0.18$0.07 per share5.16$1.71 per share0.22
Transcat, Inc. stock logo
TRNS
Transcat
$272.20M2.91$3.14 per share27.14$30.19 per share2.82
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
-$70.79M-$2.31N/AN/AN/A-226.57%-43.01%-31.63%5/6/2025 (Estimated)
Fluidigm Co. stock logo
FLDM
Fluidigm
-$59.24M-$0.78N/AN/AN/A-45.36%-40.15%-14.86%N/A
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
-$3.41M-$0.29N/AN/A-14.57%-4.64%-2.40%5/6/2025 (Estimated)
Transcat, Inc. stock logo
TRNS
Transcat
$13.65M$1.8546.0232.37N/A6.22%7.23%5.67%5/19/2025 (Estimated)

Latest EYPT, FLDM, HBIO, and TRNS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/19/2025Q4 2025
Transcat, Inc. stock logo
TRNS
Transcat
$0.66N/AN/AN/A$76.40 millionN/A
5/14/2025Q1 2025
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
-$0.65N/AN/AN/A$8.84 millionN/A
5/6/2025Q1 2025
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
-$0.0350N/AN/AN/A$19.70 millionN/A
3/5/2025Q4 2024
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
-$0.54-$0.64-$0.10-$0.64$11.02 million$11.60 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
N/AN/AN/AN/AN/A
Fluidigm Co. stock logo
FLDM
Fluidigm
N/AN/AN/AN/AN/A
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
N/AN/AN/AN/AN/A
Transcat, Inc. stock logo
TRNS
Transcat
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
N/A
5.50
5.45
Fluidigm Co. stock logo
FLDM
Fluidigm
0.68
1.45
1.03
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
0.52
2.06
0.91
Transcat, Inc. stock logo
TRNS
Transcat
0.14
2.42
1.98

Institutional Ownership

CompanyInstitutional Ownership
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
99.41%
Fluidigm Co. stock logo
FLDM
Fluidigm
76.59%
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
80.87%
Transcat, Inc. stock logo
TRNS
Transcat
98.34%

Insider Ownership

CompanyInsider Ownership
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
4.74%
Fluidigm Co. stock logo
FLDM
Fluidigm
2.90%
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
9.00%
Transcat, Inc. stock logo
TRNS
Transcat
2.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
12068.73 million65.02 millionOptionable
Fluidigm Co. stock logo
FLDM
Fluidigm
61576.49 million74.27 millionOptionable
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
49044.21 million39.69 millionOptionable
Transcat, Inc. stock logo
TRNS
Transcat
9209.31 million9.10 millionOptionable

Recent News About These Companies

Transcat Is Nearing An Inflection Point
Transcat price target lowered to $106 from $126 at H.C. Wainwright
Transcat Prepares for Q3 FY2025 Financial Results
Transcat, Inc. (TRNS) Q3 2025 Earnings Call Transcript

New MarketBeat Followers Over Time

Media Sentiment Over Time

EyePoint Pharmaceuticals stock logo

EyePoint Pharmaceuticals NASDAQ:EYPT

$6.37 -0.17 (-2.60%)
Closing price 04/25/2025 04:00 PM Eastern
Extended Trading
$6.32 -0.05 (-0.78%)
As of 08:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Fluidigm stock logo

Fluidigm NASDAQ:FLDM

Fluidigm Corporation creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Fluidigm Corporation has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

Harvard Bioscience stock logo

Harvard Bioscience NASDAQ:HBIO

$0.38 -0.01 (-3.33%)
Closing price 04/25/2025 04:00 PM Eastern
Extended Trading
$0.40 +0.02 (+6.39%)
As of 08:34 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.

Transcat stock logo

Transcat NASDAQ:TRNS

$85.13 +0.07 (+0.08%)
Closing price 04/25/2025 04:00 PM Eastern
Extended Trading
$85.11 -0.02 (-0.02%)
As of 08:19 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Transcat, Inc. provides calibration and laboratory instrument services in the United States, Canada, and internationally. It operates through two segments: Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services. This segment also provides CalTrak, a proprietary document and asset management system that is used to manage the workflow of its calibration service centers and customers' assets; and Compliance, Control and Cost, an online customer portal that provides its customers with web-based asset management capability, as well as a safe and secure off-site archive of calibration and other service records. The Distribution segment sells and rents test, measurement, and control instruments for customers' test and measurement instrumentation needs, as well as value added services, such as calibration/certification of equipment purchase, equipment rental, used equipment for sale, and equipment kitting. This segment markets and sells its products through website, digital and print advertising, proactive outbound sales, and an inbound call center. The company provides services and products to highly regulated industries, principally life science, which includes companies in the pharmaceutical, biotechnology, medical device, and other FDA-regulated industries; and additional industries, including aerospace and defense industrial manufacturing, energy and utilities, and other industries that require accuracy in processes and confirmation of the capabilities of their equipment. Transcat, Inc. was incorporated in 1964 and is headquartered in Rochester, New York.